AlCHEMY PHARM
Pioneering and InnovativeAlchemyPharm is a pioneering and innovative pharmaceutical company which is mainly engaged in pharmaceutical intermediate,advanced intermediates development and manufacturing.
R&D Center
Our lab has a dedicated R&D team that ensures efficient and professional service for product process development.
Factory
Our factory has glass reactor, stainless steel reactor, ceramic reactor, high pressure reactor, which can produce many kinds of products.
Custom synthesis
We can customize and synthesize some innovative drugs, complex advanced intermediates and APIs according to customers' needs.
Search Products
You can also email us the product information you need.
Featured products
We can produce scale from kilograms to tons to ensure that our customers' growing needs.
Rivaroxaban API and Intermediates
13726-69-7
Boc-l-hydroxyproline
15679-03-5
6-Chlorophenanthridine
367-27-1
2,4-Difluorophenol
4117-09-3
7-Bromo-1-heptene
667-27-6
Ethyl bromodifluoroacetate
37885-41-9
2',4'-Dichloropropiophenone
455-88-9
2-Fluoro-5-nitrotoluene
2420-26-0
4-Chloro-2-hydroxybenzaldehyd
![AP10896 | 1354823-36-1 | N-[(s)-(4-nitrophenoxy)phenoxyphosphinyl]-l-alanine 2-ethylbutyl ester](https://qncdn.chemcd.cn/alchemypharm/1354823-36-1.png "AP10896 | 1354823-36-1 | N-[(s)-(4-nitrophenoxy)phenoxyphosphinyl]-l-alanine 2-ethylbutyl ester")
1354823-36-1
N-[(s)-(4-nitrophenoxy)phenoxyphosphinyl]-l-alanine 2-ethylbutyl ester
415965-24-1
4-Bromo-2-fluoro-5-methylbenzoic acid
99469-99-5
3-Ethoxy-4-ethoxycarbonyl phenylacetic acid
239087-06-0
2-Fluoro-6-(trifluoromethyl)benzylamine
Latest News
Chronic kidney disease (CKD)! Astellas Roxastat is approved by the European Commission
On August 19, Astellas Pharma and FibroGen announced that the European Commission (EC) has approved the listing of EVREN
Concept Medical announces the use of MagicTouch sirolimus-coated balloons for the treatment of coronary arterial small vessel disease in the important Transform-1 randomized controlled trial to recruit index patients
Cotignola, Italy, September 3, 2020 - Concept Medical Inc., which focuses on vascular interventional drug delivery devic